GeNeuro announced it will present Phase IIb safety and efficacy data on temelimab from its ProTEct-MS study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis in Amsterdam, Netherlands. The trial was conducted at the Karolinska Institutet's Academic Specialist Center in Stockholm, Sweden. The one-year Phase 2 trial evaluated the administration of temelimab in patients with relapsing remitting MS to address disease progression independent of relapses following treatment with rituximab.

As a reminder, the topline results of the Phase 2 ProTEct-MS study, communicated in March 2022, confirmed the excellent safety profile and tolerability of higher doses of temelimab and the synergistic potential to treat neurodegeneration in addition to anti-inflammatory therapy in multiple sclerosis. Efficacy data, obtained in patients already treated effectively for inflammation, showed that temelimab has a favorable impact on key MRI parameters measuring neurodegeneration.